Protective Effects of Coenzyme Q10 on Decreased Oxidative Stress Resistance Induced by Simvastatin

Aikkarach Kettawan,1 Takayuki Takahashi,1,2 Ratchanee Kongkachuichai,3 Somsri Charoenkiatkul,3 Takeo Kishi,1 and Tadashi Okamoto1,2,*

1Laboratory of Biochemistry, Division of Health Sciences and Social Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650-8586, Japan

2Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586, Japan

3Division of Food Chemistry, Institute of Nutrition, Mahidol University, Nakhon Pathom 73170, Thailand

*To whom correspondence should be addressed. Tel: +81-78-974-1551 Fax: +81-78-974-5689 E-mail: tadashi@pharm.kobegakuin.ac.jp

Go to:

Abstract

The effects of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase), on oxidative stress resistance and the protective effects of coenzyme Q (CoQ) were investigated. When simvastatin was administered orally to mice, the levels of oxidized and reduced CoQ9 and CoQ10 in serum, liver, and heart, decreased significantly when compared to those of control. The levels of thiobarbituric acid reactive substances induced by Fe^{2+}-ascorbate in liver and heart mitochondria also increased significantly with simvastatin. Furthermore, cultured cardiac myocytes treated with simvastatin exhibited less resistance to oxidative stress, decreased time to the cessation of spontaneous beating in response to H_2O_2 addition, and decreased responsiveness to electrical field stimulation. These results suggested that oral administration of simvastatin suppresses the biosynthesis

of CoQ, which shares the same biosynthesis pathway as cholesterol up to farnesyl pyrophosphate, thus compromising the physiological function of reduced CoQ, which possesses antioxidant activity. However, these undesirable effects induced by simvastatin were alleviated by coadministering CoQ10 with simvastatin to mice. Simvastatin also reduced the activity of NADPH-CoQ reductase, a biological enzyme that converts oxidized CoQ to the corresponding reduced CoQ, while CoQ10 administration improved it. These findings may also support the efficacy of coadministering CoQ10 with statins.

Go to:

Introduction

Hypercholesterolemia is a well-known risk factor for coronary heart disease and arteriosclerosis. 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), the late-limiting enzyme in the biosynthesis of cholesterol through the mevalonate pathway, converts HMG-CoA, a trimer of acetyl CoA molecules generated from fatty acid oxidation, to mevalonic acid, which is then further metabolized to eventually produce cholesterol [1]. Among various drugs developed to reduce serum cholesterol levels and subsequent risk for coronary events, HMG-CoA reductase inhibitors (statins), have proven to be extremely useful drugs [2–5].

While statins are very clinically effective drugs, adverse reactions such as rhabdomyolysis [6, 7] have been reported. Adverse reactions often affect tissues and cells with high energy metabolism, such as skeletal muscles, myocardium and smooth muscles, and to date, ultrastructural changes, including mitochondrial dysfunction [8, 9] and swelling, increased serum creatine kinase, induction of necrosis [10] or apoptosis [11–15], and abnormalities in calcium homeostasis [16] have been reported. However, the contributing factors and protective effects have not been elucidated.

Coenzyme Q (CoQ) is an essential carrier for the mitochondrial electron transport system and plays an important role in energy production. Exogenous CoQ10 has been shown to improve energy metabolism and activate energy production by cardiac myocytes. CoQ is distributed not only in mitochondria, but also in other subcellular fractions [17–19], and some CoQ always presents as reduced CoQ (H2CoQ) [18]. H2CoQ is unstable when exposed to air, and can easily be oxidized into oxidized CoQ. In this manner, chemically unstable H2CoQ is thought to exist in the body to serve as an antioxidant. We have reported previously [20–22] that a novel cytosolic NADPH-CoQ reductase is responsible for the reduction of CoQ10 to H2CoQ10 in biomembranes. Furthermore, we observed that prolonged supplementation with CoQ10 caused a significant increase in the NADPH-CoQ reductase activity, and protected partially hepatotoxicity induced by carbon tetrachloride and H2O2. In addition, enhanced levels of H2CoQ10 and NADPH-CoQ reductase activity showed more resistant to oxidative stress than those of normal levels. These results suggested that H2CoQ10 with NADPH-CoQ reductase constituted a fundamental defense system against oxidative stress in cellular membrane. According to some reports, another reductases such as NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) [23, 24], thiredoxin reductase [25] and lipoamide dehydrogenase 1 [26, 27] may also involve in the reduction of CoQ to H2CoQ. The in vitro experiments using low-density lipoprotein (LDL) [28, 29], biological membranes [30] or lecithin liposome

membranes [31, 32] have clarified that H2CoQ possesses potent antioxidant activity. To date, two mechanisms for the antioxidant activities of H2CoQ have been clarified. In one mechanism, H2CoQ directly eliminates lipid peroxyl radicals [31, 32], and in the other, H2CoQ indirectly acts as an antioxidant by regenerating α-tocopherol from α-tocopheroxyl radicals formed by a reaction between α-tocopherol and lipid peroxyl radicals (α-tocopherol-saving action). It has been clarified that H2CoQ exhibits potent antioxidant activity through these two mechanisms.

CoQ is supplied exogenously through diet [33] or endogenously through biosynthesis [34, 35]. Therefore, supply reduction in either exogenous or endogenous CoQ may affect its physiological functions. Because cholesterol and CoQ share the same biosynthesis pathway until farnesyl pyrophosphate [34, 35], inhibition of HMG-CoA reductase, which is the rate-limiting enzyme in cholesterol biosynthesis, is likely to affect the metabolism and physiological functions of CoQ, including H2CoQ [35]. In fact, many investigators have pointed out that statin administration lowers CoQ in serum (plasma) [9, 36–38] and tissue [36], and that statins hinder normal function of the heart [39] and skeletal muscles [40].

In this study, in order to administer HMG-CoA reductase inhibitors safely and efficiently, we elucidated the change of oxidative stress resistance induced by simvastatin and its protective effects of CoQ10 were investigated.

Go to:

Materials and Methods

Reagents

All reagents were commercially available and were of reagent grade. The solvent for high performance liquid chromatography (HPLC) was purchased from Wako Pure Chemical Industries, Ltd., Osaka. Commercially available reagent grade methanol for HPLC was used after distillation. Authentic CoQ9 and CoQ10 for HPLC were donated by Nisshin Pharma Inc., Tokyo. As simvastatin, 5 mg Lipovas tablets (pharmaceutical drug, Banyu Pharmaceutical Co. Ltd., Tokyo), and as CoQ10, 30 mg LivLon Soft Capsules (dietary and health food, Nisshin Pharma Inc., Tokyo) were used in the experiment for oral administration to mice. Each compound was dissolved in drinking water and homogenized by ultrasonic treatment.

Animals

Ten week-old male specific pathogen-free (SPF) ICR mice were used. To prepare cultured cardiac myocytes, female SPF ICR mice on the fourth day of gestation were used. All mice were purchased from SLC Japan (Shizuoka). Simvastatin and CoQ10 were administered orally, and by measuring daily water intake for each mouse for three days before the study, drug solutions were prepared such that each mouse would consume the predetermined dosages. Simvastatin and CoQ10 were mixed in drinking water just prior to administration, and drinking water was prepared daily. Based on body weight, the mice were divided into four groups of five mice each [(1) control group (no simvastatin or CoQ10), (2)

simvastatin group (1 mg/day of simvastatin), (3) CoQ10 group (3 mg/day of CoQ10), and (4) simvastatin + CoQ10 group (1 mg/day of simvastatin + 3 mg/day of CoQ10)], and the dosage of simvastatin and CoQ10 was set as follows: each mouse was weighed daily, and simvastatin and CoQ10 were administered for two consecutive weeks. Simvastatin and CoQ10 were administered orally to pregnant mice from the fourth to fifteenth day of gestation (fetal ventricular myocardium was excised from pregnant mice on the fifteenth day of gestation). Mice were fed Lab MR Stock (standard feed, SLC Japan). All animal experiments were conducted in accordance with the manual compiled by the Kobe University Animal Ethics Committee.

Cultured cardiac myocyte preparation and observation

The fetal ventricular myocardium was excised from pregnant mice prepared as described above from the fourth to fifteenth day of gestation, and cultured cardiac myocytes were prepared according to the method of Goshima et al. [41]. Cardiac myocytes were cultured using Eagle MEM containing 10% fetal bovine serum under 5% CO_2 in air at 37°C for 2 days. To avoid antioxidant contamination, including CoQ10, originating from fetal bovine serum, cells were washed using 10 ml of Dulbecco's phosphate-buffered saline twice 1 h before the study, and after replacing culture solution with Eagle MEM free of fetal bovine serum, cells were incubated under 5% CO_2 in air at 37°C for at least one hour. A 1- to 2-mm-diameter cardiac myocyte sheet containing at least 104 cells was produced after cultivation for 2 days. The spontaneous beating of cultured cardiac myocyte sheet was measured in an incubator at 36 ± 1°C and under 5% CO_2 in air using a phase contrast microscope. Electrical field stimulation was performed by the method of Nakamura et al., as follows [42]: two platinum electrodes, 1 Hz, pulse length of 50 ms, and pulse amplitude of 100 V.

Preparation of mitochondria and cytosolic fraction from mice liver and heart

Intracellular fractions of mice heart and liver were prepared by differential centrifugation as described previously [18]. The purity of the cytosol and mitochondrial fractions was determined by measuring their marker enzyme activities.

Measurement of total serum cholesterol level

Total serum cholesterol was measured spectrophotometrically by the enzyme method [43].

Measurement of CoQ levels in serum, cytosolic fraction and tissue

Reduced and total CoQ (sum of oxidized and reduced CoQ) levels were measured by HPLC-electrochemical detector in accordance with the method of Okamoto et al. [44]. CoQ in the cytosolic fraction was expressed as pmol per mg protein.

Measurement of lipid peroxidation induced by Fe2+-ascorbate

Lipid peroxidation was carried out using 50 mM ascorbic acid and 5 mM FeSO4 according to the method of Takei et al. [45]. Thiobarbituric acid reactive substances (TBARS) were extracted using 3 ml of n-

butanol and were measured by the fluorometrical method (Ex: 515 nm, Em: 553 nm). The standard was 1,1,3,3-tetraethoxypropane in the TBARS assay.

Measurement of NADPH-CoQ reductase activity in cytoplasm

NADPH-CoQ activity in cytoplasm of liver and heart was measured according to the method of Takahashi et al. [46]. This activity was expressed as the amount of CoQ10 (pmol) reduced per minute per mg protein.

Protein content and data analysis

Protein content was determined as described by Lowry et al. [47]. The Student's unpaired t test were used for statistical analysis and statistical significance was assigned for any p values less than 0.05.

Go to:

Results

Changes in reduced and total CoQ levels in mouse serum, heart, liver, and their cytosolic and mitochondorial fractions induced by simvastatin administration (Table 1)

When 1 mg/kg body weight simvastatin was orally administered to mice everyday for two weeks, total serum cholesterol decreased significantly when compared to controls (no simvastatin or CoQ10). Furthermore, coadministration of simvastatin and CoQ10 lowered serum cholesterol in a similar manner. This result shows that CoQ10 itself does not affect the cholesterol lowering activity of simvastatin.

Simvastatin administration significantly lowered the levels of both serum CoQ9, the predominant homologue in mice, and CoQ10, as compared to those of control. Furthermore, simvastatin also singnificantly lowered reduced, oxidized and total CoQ10 levels, and did not affect the ratio of reduced CoQ to total CoQ.

When 3 mg/kg body weight CoQ10 was orally administered to mice everyday for two weeks, irrespective of whether CoQ10 was administered alone or with simvastatin, serum levels increased by about 6-fold. These results show that simvastatin administration does not affect the serum CoQ10 increasing level by CoQ10 administration. CoQ10 itself did not affect the levels of serum CoQ9, the main homologue in mice.

Like the levels of CoQ9 and CoQ10 in serum, the levels of CoQ9 and CoQ10 in the liver and heart were significantly lowered by simvastatin administration. Furthermore, this lowering action was observed in mitochondrial and cytosolic fractions of liver and heart.

Oxidative stress resistance-decreasing effects of simvastatin

Changes in oxidative stress resistance due to simvastatin administration were evaluated using heart and liver mitochondria and cultured cardiac myocytes.

The TBARS levels produced using Fe2+-ascorbate in heart mitochondria at 15 min after the start of the reaction for the simvastatin group was significantly higher when compared to the other groups (Table 2). At two hours after the start of the reaction, the TBARS level (mM) in the control, simvastatin, CoQ10 and simvastatin + CoQ10 groups was 0.67, 0.81, 0.63 and 0.66, respectively, and CoQ10 clearly lowered significantly the TBARS level as compared to that of simvastatin group.

Like heart mitochondria, simvastatin administration increased the amount of TBARS with time in liver mitochondria. However, unlike heart mitochondria, suppression of TBARS by CoQ10 was not seen for the first hour of the reaction, and significant suppression was confirmed only after two hours (Table 3).

Changes in oxidative stress (H2O2) resistance [42] were determined using cultured cardiac myocyte sheets prepared from fetal ventricular myocardium obtained from pregnant mice on oral simvastatin administration in terms of spontaneous beating and electrical field stimulation response (Fig. 1). Prior to the experiment, cultured cardiac myocytes were incubated with 10 μM CoQ10 (CoQ10-treated group) for 6 hours, 3 μM simvastatin (simvastatin-treated group) for 2 hours, or 10 μM CoQ10 for 6 hours and 3 μM simvastatin for 2 hours (simvastatin and CoQ10-cotreated group). Under microscopic observations, in this point, any morphological changes of cells were not observed.

When 50 μM H2O2, an active oxygen species, was added to untreated cultured cardiac myocytes, beating stopped after 17 min. Furthermore, immediately after cessation, electric field stimulation was applied to the cells. When the time for the cells to respond to the stimulation was measured, electrical field-stimulated beating continued for 28 min. With cardiac myocytes treated by simvastatin, the length of time to cessation was 13 min, and the electric field stimulation response time was 18 min, thus suggesting that simvastatin lowers oxidative stress resistance. On the other hand, CoQ10 increased the oxidative stress resistance of cardiac myocytes, and when compared to those of simvastatin group, spontaneous beating and electric field stimulation response time were significantly longer. The results were the same when 100 μM H2O2 was added to cardiac myocytes, but the effects of CoQ10 on spontaneous beating and electric field stimulation response time were not as great as when 50 μM H2O2 was added.

NADPH-CoQ reductase activity-lowering effect of simvastatin (Fig 2)

NADPH-CoQ reductase is one of the CoQ reductases in the cytoplasm, and we have reported previously that NADPH-CoQ reductase activity changes due to various oxidative stresses [48].

As shown in Fig. 2, when compared to the control group, cytoplasmic NADPH-CoQ reductase activity in the liver and heart in the simvastatin group were significantly lower when compared to those of control. CoQ10 administration increased NADPH-CoQ reductase activity in the liver and heart, and the NADPH-CoQ reductase activity in the simvastatin and CoQ10-cotreated group was higher than that of the simvastatin group.

Go to:

Discussion

The nutritional sufficiency of CoQ is affected by both endogenous and exogenous CoQ, and a reduction in one source is thought to markedly affect its physiological function. We reported previously [49] that serum CoQ10 levels in patients on total parenteral nutrition (TPN) decreased significantly after TPN and never reached zero following TPN. These results suggest that the decrease in serum CoQ10 levels after TPN is dependent on dietary (exogenous) CoQ10 and that the residual serum CoQ10 levels following TPN are dependent on biosynthesized (endogenous) CoQ10. However, the physiological changes induced by insufficient supply of endogenous CoQ10 have been unknown.

The CoQ biosynthesis pathway for eukaryotic cells has already been clarified [34, 35]. CoQ shares the same biosynthetic pathway as cholesterol up to farnesyl pyrophosphate, and statins, which inhibit the rate-limiting enzyme of cholesterol biosynthesis, block the upstream section of the CoQ biosynthesis pathway. Therefore, statins affect CoQ biosynthesis greatly. Furthermore, the CoQ level in the body has been reported to decrease after the age of 20 years, and this decrease is marked in tissues with high energy metabolism, such as the heart [50]. Decreased CoQ10 might be thus a serious problem, as most hypercholesterolemia patients who take statins are elderly.

Decrease in CoQ levels induced by oral administration of HMG-CoA reductase inhibitor

As shown in Table 1, oral administration of simvastatin significantly decreased not only serum cholesterol levels, but also serum and tissue CoQ9 and CoQ10 levels. Simvastatin also decreased both reduced and oxidized forms of CoQ9 and CoQ10. Many investigators have pointed out that statins lower serum and tissue CoQ levels [9, 36–38], but the effects of decreased CoQ on the body have not been fully elucidated. Folkers et al. reported that patients on statin therapy exhibited cardiac dysfunction [39]. The most important physiological action of CoQ10 is to improve energy metabolism by serving as an essential factor in the mitochondrial electron transfer system, and this action is accepted as the physiological action of CoQ10. Therefore, reduced CoQ levels may affect skeletal muscles and myocardium with active energy metabolism. In fact, muscle pain or weakness with high creatine kinase levels is the major adverse effects of statins [2]. In the present study, the levels of CoQ, in cytoplasm where NADPH-CoQ reductase are present, as well as in the mitochondria were measured (Table 1), and the results confirmed that statin administration reduces CoQ levels in mitochondria and cytoplasm among intracellular organelles.

Decreased oxidative stress resistance due to oral administration of HMG-CoA reductase inhibitor

In addition to energy production activation, another important physiological action of CoQ10 is as an antioxidant in vivo. Therefore, when simvastatin administration lowers CoQ levels in the body, endogenous antioxidative function may be affected to some degree. In general, orally taken oxidized CoQ10 is absorbed by epithelial cells in the small intestine and transported via the lymphatic system to the liver, and is reduced by NADPH-CoQ reductase to become H2CoQ10, which has potent antioxidant action [20–22]. In human serum (plasma), CoQ10 is mostly present as H2CoQ10, and even if oxidized CoQ10 is administered exogenously, the ratio of reduced CoQ10 to total CoQ10 remains the same [51]. Therefore, H2CoQ10, which is extremely unstable in air, is thought to exist in the body due to its role as an antioxidant.

In the present study, oral administration of statin decreased the resistance of heart and liver mitochondria to lipid peroxidation induced by Fe^{2+}-ascorbate and transiently increased the production of TBARS (Tables 2 and 3). This increase in TBARS was alleviated by oral administration of CoQ10. Furthermore, oral administration of CoQ10 increased also NADPH-CoQ reductase activity, which was decreased by statin administration (Fig. 2). On the other hand, simvastatin also induced cessation of both spontaneous beating and stimulation-elicited beating in cultured cardiac myocytes (Fig. 1). This simvastatin-contractile impairment was prevented partially by pretreatment of cultured cardiac myocytes with 10 μM CoQ10. These results suggest that by coadministering CoQ10 and statin, sufficient amounts of H2CoQ10 are supplied to the body and maintained, thus alleviating the decreased oxidative stress resistance caused by statin administration.

Necessity of CoQ10 during oral administration of HMG-CoA reductase inhibitor

In 2001, the Ministry of Health, Labour and Welfare in Japan permitted the use of CoQ10 as a food additive as long as no claims were made about its pharmacological effectiveness and application. Now, many CoQ10-containing dietary and helath supplements are commercially available in Japan. While people mostly take CoQ10 for health maintenance or nutritional supplementation, as the size of the elderly population continues to increase in Japan, it is necessary to consider to the adverse reactions caused by drugs that are frequently prescribed to the elderly. The present study showed that statin administration decreased the body's resistance to oxidative stress, and one of the factors may be decreased CoQ levels. Therefore, we clarifies that when administering statin, it is desirable to elevate CoQ to normal levels, thus maintaining resistance to various oxidative stresses.

Go to:

Go to:

References

1. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 1990;343:425–430. [PubMed: 1967820]

2. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 2000;101:207–213. [PubMed: 10637210]

3. Bays H. Statin safety: an overview and assessment of the data—2005. Am. J. Cardiol. 2006;97:6C–26C.

4. McKenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R. National lipid association statin safety assessment task force.: Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 2006;97:89C–94C.

5. Tobert J.A., Bell G.D., Birtwell J., James I., Kukovetz W.R., Pryor J.S., Buntinx A., Holmes J.B., Chao Y.S., Bolognese J.A. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J. Clin. Invest. 1982;69:913–919. [PMCID: PMC370145] [PubMed: 6918402]

6. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 2006;97:44C–51C. [PubMed: 16581328]

7. Law M., Rudnicka A.R. Satin safety: a systematic review. Am. J. Cardiol. 2006;97:52C–60C.

8. Jones S.P., Teshima Y., Akao M., Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ. Res. 2003;93:697–699. [PubMed: 14512440]

9. De Pinieux G., Chariot P., Ammi-Said M., Louarn I., Lejonc J.L., Astier A., Jacotot B., Gherardi R. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. 1996;42:333–337. [PMCID: PMC2042680] [PubMed: 8877024]

10. Nakahara K., Kuriyama M., Sonoda Y., Yoshidome H., Nakagawa H., Fujiyama J., Higuchi I., Osame M. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 1998;152:99–106. [PubMed: 9772205]

11. Demyanets S., Kaun C., Pfaffenberger S., Hohensinner P.J., Rega G., Pammer J., Maurer G., Huber K., Wojta J. Hydroxymethyl-glutaryl-coenzyme A reductase inbitors induce apoptosis in human cardiac myocytes in vitro. Biochem. Pharmacol. 2006;71:1324–1330. [PubMed: 16540096]

12. Rabkin S.W., Kong J.Y. Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicol. Appl. Pharmacol. 2003;193:346–355. [PubMed: 14678744]

13. Kaneta S., Satoh K., Kano S., Kanda M., Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis. 2003;170:237–243. [PubMed: 14612203]

14. Erl W., Hristov M., Neureuter M., Yan Z.Q., Hansso G.K., Weber P.C. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular sooth muscle cells. Atherosclerosis. 2003;169:251–258. [PubMed: 12921976]

15. Fouty B.W., Rodman D.M. Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle through a p27Kip1-independent pathway. Circ. Res. 2003;92:501–509. [PubMed: 12600884]

16. Sirvent P., Mercier J., Vassort G., Lacampagne A. Simvastatin triggers mitochondrial-induced Ca2+ signaling alteration in skeletal muscle. Biochem. Biophys. Res. Commun. 2005;329:1067–1075. [PubMed: 15752763]

17. Kalén A., Norling B., Appelkvist E.L., Dallner G. Ubiquinone biosynthesis by the microsomal fraction from rat liver. Biochim. Biophys. Acta. 1987;926:70–78. [PubMed: 3651503]

18. Takahashi T., Okamoto T., Mori K., Sayo H., Kish T. Distribution of ubiquinone and ubiquinol homologues in rat tissues and subcellular fractions. Lipids. 1993;28:803–809. [PubMed: 8231656]

19. Kalén A., Appelkvist E.L., Chojnacki T., Dallner G. Nonaprenyl-4-hydroxybenzoate transferase. An enzyme involved in ubiquinone biosynthesis, in the endoplasmic reticulum-Golgi system of rat liver. J. Biol. Chem. 1990;265:1158–1164. [PubMed: 2295606]

20. Takahashi T., Shitashige M., Okamoto T., Kishi T., Goshima K. A nevel ubiquinone reductase activity in rat cytosol. FEBS Lett. 1992;314:331–334. [PubMed: 1468565]

21. Takahashi T., Yamaguchi T., Shitashige M., Okamoto T., Kishi T. Reduction of ubiquinone in membrane lipids by rat liver cytosol and its involvement in the cellular defense system against lipid peroxidation. Biochem. J. 1995;309:883–890. [PMCID: PMC1135714] [PubMed: 7639706]

22. Kishi T., Takahashi T., Mizobuchi S., Mori K., Okamoto T. Effect of dicumarol, a NAD(P)H: quinone acceptor oxidoreductase 1 (DT-diaphorase) inhibitor on ubiquinone redox cycling in cultured rat hepatocytes. Free Radic. Res. 2002;36:413–419. [PubMed: 12069105]

23. Beyer R.E., Segura-Aguilar J., Di Bernardo S., Cavazzoni M., Fato R., Fiorentini D., Galli M.C., Setti M., Landi L., Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. USA. 1996;93:2528–2532. [PMCID: PMC39831] [PubMed: 8637908]

24. Landi L., Fiorentini D., Galli M.C., Segura-Aguilar J., Beyer R.E. DT-diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function. Free Radic. Biol. Med. 1997;22:329–335. [PubMed: 8958158]

25. Xia L., Nordan T., Olsson J.M., Damdimopoulos A., Bjorkhem-Bergman L., Nalvarte I., Eriksson L.C., Arner E.S., Spyrou G., Bjornstedt M. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J. Biol. Chem. 2003;278:2141–2146. [PubMed: 12435734]

26. Olsson J.M., Xia L., Eriksson L.C., Bjornstedt M. Ubiquinone is reduced by lipoamide dehydrogenase and this reaction is potently stimulated by zinc. FEBS Lett. 1999;448:190–192. [PubMed: 10217438]

27. Xia L., Bjornstedt M., Nordman T., Eriksson L.C., Olsson J.M. Reduction of ubiquinone by lipoamide dehydrogenase. An antioxidant regenerating pathway. Eur. J. Biochem. 2001;268:1486–1490. [PubMed: 11231302]

28. Frei B., Kim M.C., Ames B.N. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc. Natl. Acad. Sci. USA. 1990;87:4879–4883. [PMCID: PMC54222] [PubMed: 2352956]

29. Stocker R., Bowry V.W., Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc. Natl. Acad. Sci. USA. 1991;88:1646–1650. [PMCID: PMC51081] [PubMed: 2000375]

30. Kagan V.E., Serbinova E.A., Koynova G.M., Kitanova S.A., Tyurin V.A., Stoytchev T.S., Quinn P.J., Packer L. Antioxidant action of ubiquinol homologues with different isoprenoid chain length in biomembranes. Free Radic. Biol. Med. 1990;9:117–126. [PubMed: 2227528]

31. Yamamoto Y., Komuro E., Niki E. Antioxidant activity of ubiquinol in solution and phosphatidylcholine liposome. J. Nutr. Sci. Vitaminol. 1990;36:505–511. [PubMed: 2097322]

32. Landi L., Cabrini L., Fiorentini D., Stefanelli C., Pedulli G.F. The antioxidant activity of ubiquinol-3 in homogeneous solution and in liposomes. Chem. Phys. Lipids. 1992;61:121–130. [PubMed: 1511485]

33. Kamei M., Fujita T., Kanbe T., Sasaki K., Oshiba K., Otani S., Matsui-Yuasa I., Morisawa S. The distribution and content of ubiquinone in foods. Int. J. Vitam. Nutr. Res. 1986;56:57–63. [PubMed: 3710719]

34. Szkopinska A. Ubiquinone. Biosynthesis of quinine ring and its isoprenoid side chain. Intracellular localization. Acta Biochim. Pol. 2000;47:469–480. [PubMed: 11051212]

35. Crane F.L. Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr. 2001;20:591–598. [PubMed: 11771674]

36. Willis R.A., Folkers K., Tucker J.L., Ye C.Q., Xia L.J., Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. USA. 1990;87:8928–8930. [PMCID: PMC55073] [PubMed: 2247467]

37. Ghirlanda G., Oradei A., Manto A., Lippa S., Uccioli L., Caputo S., Greco A.V., Littarru G.P. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 1993;33:226–229. [PubMed: 8463436]

38. Passi S., Stancato A., Aleo E., Dmitrieva A., Littarru G.P. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors. 2003;18:113–124. [PubMed: 14695926]

39. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA. 1990;87:8931–8934. [PMCID: PMC55074] [PubMed: 2247468]

40. Sirvent P., Bordenave S., Vermaelen M., Roels B., Vassort G., Mercier J., Raynaud E., Lacampagne A. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem. Biophys. Res. Commun. 2005;338:1426–1434. [PubMed: 16271704]

41. Goshima K. Ouabain-induced arrhythmias of single isolated cardiac myocytes and cell clusters cultured in vitro and their improvement by quinidine. J. Mol. Cell, Cardiol. 1977;9:7–23. [PubMed: 557567]

42. Nakamura T.Y., Goda K., Okamoto T., Kishi T., Nakamura T., Goshima K. Contractile and morphological impairment of cultured fetal mouse myocytes induced by oxygen radicals and oxidants. Correlation with intracellular Ca2+ concentration. Circ. Res. 1993;73:758–770. [PubMed: 8396508]

43. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974;20:470–475. [PubMed: 4818200]

44. Okamoto T., Fukunaga Y., Ida Y., Kishi T. Determination of reduced and total ubiquinones in biological materials by liquid chromatography with electrochemical detection. J. Chromatogr. 1988;430:11–19. [PubMed: 3215946]

45. Takei M., Hiramatsu M., Mori A. Inhibitory effects of calcium antagonists on mitochondrial swelling induced by liquid peroxidation or arachidonic acid in the rat brain in vitro. Nurochem. Res. 1994;19:1199–1206.

46. Takahashi T., Okamoto T., Kishi T. Characterization of NADPH-dependent ubiquinone reductase activity in rat liver cytosol: effect of various factors on ubiquinone-reducing activity and discrimination from other quinone reductase. J. Biochem. 1996;119:256–263. [PubMed: 8882715]

47. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951;193:265–275. [PubMed: 14907713]

48. Takahashi T., Sugimoto N., Takahata K., Okamoto T., Kishi T. Cellular antioxidant defense by a ubiquinol-regenerating system coupled with cytosolic NADPH-dependent ubiquinone reductase: Protective effect against carbon tetrachloride-induced hepatotoxicity in the rat. Biol. Pharm. Bull. 1996;19:1005–1012. [PubMed: 8874805]

49. Okamoto T., Fukui K., Nakamoto M., Kishi T., Kanamori R., Kataoka K., Nishii S., Kishi H., Hiraoka E., Okada A. Serum levels of coenzyme Q10 and lipids in patients during tatal parenteral nutrition. J. Nutr. Sci. Vitaminol. 1986;32:1–12. [PubMed: 3086525]

50. Kal˙n A., Appelkvist E.L., Dallner G. Age-related changes in the lipid composition of rat and human tissues. Lipids. 1989;24:579–584. [PubMed: 2779364]

51. Okamoto T., Matsuya T., Fukunaga Y., Kishi T., Yamagami T. Human serum ubiquinol-10 levels and relationship to serum lipids. Int. J. Vitam. Nutr. Res. 1989;59:288–292. [PubMed: 2599795]

Go to:

Figures and Tables

Fig. 1

Protective effect of Coenzyme Q10 on beating impairment of cultured cardiac myocytes induced by simvastatin. The value given are means ± SD (n = 5). a)$p < 0.05$, b)$p < 0.01$, and c)$p < 0.001$ vs control (untreated) group. d)$p < 0.05$, e)$p < 0.01$, and f)$p < 0.001$ vs simvastatin-treated group.

Fig. 2

Effect of simvastatin on cytosolic NADPH-CoQ reductase activities in heart and liver. The value given are means ± SD (n = 5). a)$p<0.05$, b)$p<0.01$, and c)$p<0.001$ vs control (untreated) group. d)$p<0.05$, e)$p<0.01$, and f)$p<0.001$ vs simvastatin-treated group.

Table 1

Effect of simvastatin on serum cholesterol and Coenzyme Q contents in Serum, Heart and Liver

	Administration			
	Control	Sim	CoQ10	Sim + CoQ10
Serum				
Cholesterol (mg/dl)	131 ± 25	94 ± 31*	141 ± 15	90 ± 22*

	Administration			
	Control	Sim	CoQ10	Sim + CoQ10
Total CoQ9 (ng/ml)1	71.9 ± 3.1	60.2 ± 8.9*	75.8 ± 3.4	66.1 ± 6.4*
Reduced CoQ9 (ng/ml)	58.0 ± 2.2	48.0 ± 8.8*	62.9 ± 3.7	54.3 ± 6.8
Reduced/Total (%)2	80.4 ± 3.0	79.3 ± 3.9	83.0 ± 1.9	81.2 ± 5.5
Total CoQ10 (ng/ml)1	24.4 ± 1.3	19.3 ± 1.5**	155.3 ± 48.2**	143.7 ± 56.8**
Reduced CoQ10 (ng/ml)	19.2 ± 1.7	15.4 ± 1.5**	128.7 ± 37.3**	115.6 ± 54.2**
Reduced/Total (%)2	78.5 ± 2.6	80.1 ± 4.9	83.3 ± 2.9*	78.0 ± 6.1
Liver				
Total CoQ9 (µg/g)1	39.3 ± 5.0	30.5 ± 3.1*	44.6 ± 2.8*	37.4 ± 5.6
Reduced CoQ9 (µg/g)	24.7 ± 4.9	18.4 ± 2.6*	29.8 ± 2.6*	23.5 ± 5.7
Reduced/Total (%)2	62.6 ± 6.0	60.2 ± 4.9	66.8 ± 3.7*	63.2 ± 6.7
Total CoQ10 (µg/g)1	3.3 ± 0.6	2.5 ± 0.3*	9.1 ± 1.8**	8.8 ± 2.3**
Reduced CoQ10 (µg/g)	2.0 ± 0.4	1.4 ± 0.3*	6.1 ± 1.4**	5.6 ± 1.5**
Reduced/Total (%)2	59.8 ± 4.1	57.3 ± 4.2	66.0 ± 4.9*	64.0 ± 4.1*
Mitochondria				
Total CoQ101 (pmol/mg protein)	13.7 ± 1.3	10.0 ± 1.5**	21.8 ± 2.2**	17.0 ± 1.1*
Cytosol				
Total CoQ101 (pmol/mg protein)	2.5 ± 0.2	2.4 ± 0.1*	3.3 ± 0.2**	3.0 ± 0.2**
Heart				

	Administration			
	Control	Sim	CoQ10	Sim + CoQ10
Total CoQ9 (µg/g)1	214.5 ± 36.0	171.8 ± 22.4*	225.4 ± 30.9	186.1 ± 6.3*
Reduced CoQ9 (µg/g)	91.5 ± 8.7	71.0 ± 10.1*	98.8 ± 9.5	81.9 ± 8.9*
Reduced/Total (%)2	43.4 ± 5.8	41.4 ± 2.8	44.4 ± 6.4	45.0 ± 4.0
Total CoQ10 (µg/g)1	24.8 ± 5.2	21.0 ± 3.2*	26.2 ± 3.1	23.1 ± 3.4
Reduced CoQ10 (µg/g)	8.5 ± 1.2	7.0 ± 1.2*	9.9 ± 1.2	8.0 ± 1.4
Reduced/Total (%)2	35.0 ± 6.8	33.8 ± 3.3	38.2 ± 4.8	35.2 ± 6.5
Mitochondria				
Total CoQ101 (pmol/mg protein)	284.8 ± 18.7	247.8 ± 17.7*	313.9 ± 11.4*	270.9 ± 20.8
Cytosol				
Total CoQ101 (pmol/mg protein)	17.4 ± 0.8	13.4 ± 1.1*	16.8 ± 1.5	15.9 ± 1.0

View it in a separate window

Control: untreated group, Sim: simvastatin-treated group, CoQ10: CoQ10-treated group, Sim + CoQ10: simvastatin and CoQ10-cotreated group. The values given are means ± SD (n = 5). 1 Total CoQn is the sum of both reduced and oxidized form of CoQn. 2 Reduced CoQ10/Total CoQ10 × 100. *$p<0.05$, **$p<0.005$ vs control (untreated) group.

Table 2

Protective effect of Coenzyme Q10 on lipid peroxidation of heart mitochondria induced by Fe^{2+}-ascorbate

Group	TBARS (mM)		

	15 min	30 min	1 h	2 h
Control	0.46 ± 0.04e)	0.67 ± 0.03	0.61 ± 0.02d)	0.67 ± 0.01f)
Sim	0.60 ± 0.05b)	0.72 ± 0.03	0.71 ± 0.07a)	0.81 ± 0.02c)
CoQ10	0.46 ± 0.01e)	0.57 ± 0.02b), f)	0.57 ± 0.03d)	0.63 ± 0.04f)
Sim + CoQ10	0.41 ± 0.01f)	0.61 ± 0.06d)	0.60 ± 0.02d)	0.66 ± 0.02f)

View it in a separate window

Control: untreated group, Sim: simvastatin-treated group, CoQ10: CoQ10-treated group, Sim + CoQ10: simvastatin and CoQ10-cotreated group. The values given are means ± SD (n = 5). a)$p<0.05$, b)$p<0.01$, and c)$p<0.001$ vs control (untreated) group at each indicated time. d)$p<0.05$, e)$p<0.01$, and f)$p<0.001$ vs simvastatin-treated group at each indicated time.

Table 3

Protective effect of Coenzyme Q10 on lipid peroxidation of liver mitochondria induced by Fe^{2+}-ascorbate

Group	TBARS (mM)			
	15 min	30 min	1 h	2 h
Control	0.69 ± 0.02	0.86 ± 0.08	0.80 ± 0.04d)	0.85 ± 0.05c)
Sim	0.71 ± 0.03	0.89 ± 0.03	0.94 ± 0.06b)	0.94 ± 0.02a)
CoQ10	0.65 ± 0.03c)	0.74 ± 0.05a), d)	0.63 ± 0.08b), e)	0.66 ± 0.08b), e)
Sim + CoQ10	0.72 ± 0.03	0.88 ± 0.03	0.89 ± 0.06a)	0.86 ± 0.05c)

View it in a separate window

Control: untreated group, Sim: simvastatin-treated group, CoQ10: CoQ10-treated group, Sim + CoQ10: simvastatin and CoQ10-cotreated group. The values given are means ± SD (n = 5). a)$p<0.05$ and b)$p<0.01$ vs control (untreated) group at each indicated time. c)$p<0.05$, d)$p<0.01$, and e)$p<0.001$ vs simvastatin-treated group at each indicated time.

Abstract